LAVIPHARM S.A. NA EO 1 (F:BXA0) — Stock Price
LAVIPHARM S.A. NA EO 1 (F:BXA0) is currently trading at €1.48 EUR, up 0.13% today. Over the past 52 weeks, shares have ranged between €0.72 and €1.78. This page tracks LAVIPHARM S.A. NA EO 1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see LAVIPHARM S.A. NA EO 1 (BXA0) cash flow conversion.
LAVIPHARM S.A. NA EO 1 (BXA0) Stock Price Chart — Daily History & Trading Volume
The chart below tracks LAVIPHARM S.A. NA EO 1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
LAVIPHARM S.A. NA EO 1 Income Statement — Revenue, Profit & Earnings by Year
LAVIPHARM S.A. NA EO 1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue | €52.95 Million | €47.84 Million | €39.06 Million | €39.72 Million |
| Cost of Revenue | €27.87 Million | €25.69 Million | €21.43 Million | €23.84 Million |
| Gross Profit | €25.08 Million | €22.15 Million | €17.62 Million | €15.89 Million |
| Research & Development | €631.00K | €430.00K | €854.00K | €812.00K |
| SG&A | €9.46 Million | €9.12 Million | €2.33 Million | €2.49 Million |
| Total Operating Expenses | €47.47 Million | €43.25 Million | €35.32 Million | €34.34 Million |
| Operating Income | €5.47 Million | €4.59 Million | €3.73 Million | €5.38 Million |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | €2.01 Million | €2.17 Million | €1.64 Million | €1.83 Million |
| Income Before Tax | €3.60 Million | €3.22 Million | €2.26 Million | €2.75 Million |
| Income Tax Expense | — | — | — | — |
| Net Income | €8.98 Million | €1.87 Million | €834.00K | €1.72 Million |
LAVIPHARM S.A. NA EO 1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes LAVIPHARM S.A. NA EO 1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Assets | €125.48 Million | €114.79 Million | €114.17 Million | €52.74 Million |
| Total Current Assets | €45.00 Million | €45.65 Million | €45.60 Million | €25.96 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | — | €3.00K | €1.00K | — |
| Net Receivables | €15.61 Million | €21.70 Million | €17.13 Million | €15.66 Million |
| Inventory | €19.46 Million | €14.83 Million | €10.23 Million | €8.97 Million |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | €72.52 Million | €72.02 Million | €73.86 Million | €62.68 Million |
| Total Current Liabilities | €39.12 Million | €35.80 Million | €45.74 Million | €41.07 Million |
| Long-term Debt | €12.17 Million | €12.70 Million | €3.96 Million | €4.00 Million |
| Net Debt | €17.15 Million | €12.26 Million | €7.32 Million | €23.65 Million |
| Total Stockholder Equity | €52.98 Million | €42.74 Million | €40.28 Million | €-9.98 Million |
| Retained Earnings | €-23.85 Million | €-32.59 Million | €-34.27 Million | €-162.11 Million |
LAVIPHARM S.A. NA EO 1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how LAVIPHARM S.A. NA EO 1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | €4.64 Million | €284.00K | €3.35 Million | €4.11 Million |
| Capital Expenditures | €9.64 Million | €4.05 Million | €35.62 Million | €1.92 Million |
| Free Cash Flow | €-5.00 Million | €-3.77 Million | €-32.27 Million | €2.19 Million |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | — | — | — | — |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | — | — | — | — |
| Depreciation | €4.58 Million | €4.21 Million | €1.71 Million | €1.65 Million |
| Change in Cash | €-2.70 Million | €-9.81 Million | €16.60 Million | €-294.00K |
LAVIPHARM S.A. NA EO 1 Earnings History — EPS Actual vs. Analyst Estimates
Track LAVIPHARM S.A. NA EO 1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for LAVIPHARM S.A. NA EO 1.